|Bid||295.77 x 13700|
|Ask||295.87 x 21700|
|Day's range||294.80 - 297.96|
|52-week range||242.00 - 320.42|
|Beta (5Y monthly)||0.14|
|PE ratio (TTM)||42.67|
|Forward dividend & yield||2.94 (0.99%)|
|Ex-dividend date||02 Sept 2021|
|1y target est||N/A|
Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines. These analyses from a comprehensive set of real-world studies will be presented at the global International Society for Influenza and other Respiratory Virus Diseases (ISIRV)-World Health Organization (WHO) Virtual Conference from October 19-21, 2021.
During its annual R&D investment briefing earlier today, CSL Limited (ASX:CSL; USOTC:CSLLY) highlighted progress from its novel pipeline that spans six therapeutic areas (immunology, hematology, respiratory, cardiovascular and metabolic, transplant, influenza), four scientific platforms (plasma fractionation, recombinant technology, cell and gene therapy, vaccines) and two businesses (CSL Behring and Seqirus).
Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX: CSL), today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine, for an expanded age indication for children as young as six months old.4 With this approval, FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine in the U.S., is now indicated for everyone eligible to receive